Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Non-Current Debt (2022 - 2025)

BioXcel Therapeutics has reported Non-Current Debt over the past 4 years, most recently at $84.7 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $84.7 million for Q4 2025, down 17.41% from a year ago — trailing twelve months through Dec 2025 was $84.7 million (down 17.41% YoY), and the annual figure for FY2025 was $84.7 million, down 17.41%.
  • Non-Current Debt for Q4 2025 was $84.7 million at BioXcel Therapeutics, down from $92.3 million in the prior quarter.
  • Over the last five years, Non-Current Debt for BTAI hit a ceiling of $104.4 million in Q3 2024 and a floor of $61.1 million in Q2 2022.
  • Median Non-Current Debt over the past 4 years was $97.5 million (2025), compared with a mean of $94.9 million.
  • Biggest five-year swings in Non-Current Debt: skyrocketed 58.57% in 2023 and later dropped 17.41% in 2025.
  • BioXcel Therapeutics' Non-Current Debt stood at $93.1 million in 2022, then rose by 8.11% to $100.6 million in 2023, then rose by 1.9% to $102.5 million in 2024, then dropped by 17.41% to $84.7 million in 2025.
  • The last three reported values for Non-Current Debt were $84.7 million (Q4 2025), $92.3 million (Q3 2025), and $97.5 million (Q2 2025) per Business Quant data.